Where Disc Medicine Stands With Analysts
Portfolio Pulse from Benzinga Insights
Disc Medicine (NASDAQ:IRON) has received positive analyst ratings in the last quarter, with 6 bullish and 4 somewhat bullish ratings. Over the past 3 months, 10 analysts have offered 12-month price targets for Disc Medicine, with an average price target of $63.2, an increase of 32.0% from the previous average price target of $47.88.
August 14, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Disc Medicine has received positive analyst ratings, which could potentially boost its stock price.
Analyst ratings often influence investor sentiment and can impact a company's stock price. In this case, Disc Medicine has received predominantly positive ratings, which could lead to an increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100